| Identification | Back Directory | [Name]
MM 419447 | [CAS]
1092457-78-7 | [Synonyms]
MM 419447
Linaclotide Impurity 4
L-Cysteine, L-cysteinyl-L-cysteinyl-L-α-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-, cyclic (1→6),(2→10),(5→13)-tris(disulfide) | [Molecular Formula]
C50H70N14O19S6 | [MOL File]
1092457-78-7.mol | [Molecular Weight]
1363.55 |
| Chemical Properties | Back Directory | [Boiling point ]
1951.7±65.0 °C(Predicted) | [density ]
1.60±0.1 g/cm3(Predicted) | [solubility ]
DMSO : 100 mg/mL (73.34 mM; Need ultrasonic) | [form ]
Solid | [pka]
2.96±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C)[1]. | [in vivo]
MM 419447 (10 mg/kg; p.o.) treatment shows the Cmax, AUC0-6 and t1/2 values of 27 ng/mL, ≤ 29.7 ng h/mL and 0.33 hours, respectively[1] | Animal Model: | Female Sprague-Dawley rats[1] | | Dosage: | 10 mg/kg | | Administration: | P.o. (Pharmacokinetic Analysis) | | Result: | The Cmax, AUC0-6 and Tmax were 27 ng/mL, ≤ 29.7 ng h/mL and 0.33 hours, respectively. |
| [References]
[1] Busby RW, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344 DOI:10.1124/jpet.112.199430 |
|
|